These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 16110022)

  • 1. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutation and microsatellite instability status for the prediction of survival in adjuvant-treated colon cancer patients.
    Watanabe T; Kanazawa T; Kazama Y; Tanaka J; Tanaka T; Ishihara S; Nagawa H
    J Clin Oncol; 2005 Dec; 23(35):9031-2; author reply 9032-3. PubMed ID: 16339756
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
    Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
    Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.
    Kim GP; Colangelo LH; Wieand HS; Paik S; Kirsch IR; Wolmark N; Allegra CJ;
    J Clin Oncol; 2007 Mar; 25(7):767-72. PubMed ID: 17228023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.
    Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N
    Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemosensitivity and survival in gastric cancer patients with microsatellite instability.
    Oki E; Kakeji Y; Zhao Y; Yoshida R; Ando K; Masuda T; Ohgaki K; Morita M; Maehara Y
    Ann Surg Oncol; 2009 Sep; 16(9):2510-5. PubMed ID: 19565284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low microsatellite instability is associated with poor prognosis in stage C colon cancer.
    Kohonen-Corish MR; Daniel JJ; Chan C; Lin BP; Kwun SY; Dent OF; Dhillon VS; Trent RJ; Chapuis PH; Bokey EL
    J Clin Oncol; 2005 Apr; 23(10):2318-24. PubMed ID: 15800322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
    Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
    Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
    Elsaleh H; Iacopetta B
    Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients.
    Meng WJ; Sun XF; Tian C; Wang L; Yu YY; Zhou B; Gu J; Xia QJ; Li Y; Wang R; Zheng XL; Zhou ZG
    Oncology; 2007; 72(1-2):82-8. PubMed ID: 18004081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
    Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
    Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.
    Migliavacca M; Ottini L; Bazan V; Agnese V; Corsale S; Macaluso M; Lupi R; Dardanoni G; Valerio MR; Pantuso G; Di Fede G; Tomasino RM; Gebbia N; Mariani-Costantini R; Russo A
    J Cell Physiol; 2004 Sep; 200(3):476-85. PubMed ID: 15254976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A substantial proportion of microsatellite-unstable colon tumors carry TP53 mutations while not showing chromosomal instability.
    Westra JL; Boven LG; van der Vlies P; Faber H; Sikkema B; Schaapveld M; Dijkhuizen T; Hollema H; Buys CH; Plukker JT; Kok K; Hofstra RM
    Genes Chromosomes Cancer; 2005 Jun; 43(2):194-201. PubMed ID: 15729700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of microsatellite instability in resectable pancreatic cancer.
    Nakata B; Wang YQ; Yashiro M; Nishioka N; Tanaka H; Ohira M; Ishikawa T; Nishino H; Hirakawa K
    Clin Cancer Res; 2002 Aug; 8(8):2536-40. PubMed ID: 12171881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.